Madrigal Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Madrigal Pharmaceuticals's earnings have been declining at an average annual rate of -33.3%, while the Biotechs industry saw earnings growing at 17.7% annually.
Key information
-33.3%
Earnings growth rate
-29.9%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | n/a |
| Return on equity | -92.2% |
| Net Margin | n/a |
| Next Earnings Update | 07 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Madrigal Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -374 | 108 | 272 |
| 30 Sep 23 | 0 | -347 | 76 | 272 |
| 30 Jun 23 | 0 | -330 | 61 | 270 |
| 31 Mar 23 | 0 | -315 | 55 | 260 |
| 31 Dec 22 | 0 | -295 | 48 | 245 |
| 30 Sep 22 | 0 | -274 | 45 | 228 |
| 30 Jun 22 | 0 | -256 | 41 | 214 |
| 31 Mar 22 | 0 | -247 | 40 | 207 |
| 31 Dec 21 | 0 | -242 | 37 | 205 |
| 30 Sep 21 | 0 | -236 | 32 | 206 |
| 30 Jun 21 | 0 | -231 | 29 | 204 |
| 31 Mar 21 | 0 | -219 | 24 | 197 |
| 31 Dec 20 | 0 | -202 | 22 | 185 |
| 30 Sep 20 | 0 | -171 | 21 | 156 |
| 30 Jun 20 | 0 | -134 | 20 | 122 |
| 31 Mar 20 | 0 | -105 | 22 | 93 |
| 31 Dec 19 | 0 | -84 | 23 | 72 |
| 30 Sep 19 | 0 | -68 | 23 | 56 |
| 30 Jun 19 | 0 | -55 | 24 | 43 |
| 31 Mar 19 | 0 | -42 | 19 | 33 |
| 31 Dec 18 | 0 | -33 | 15 | 25 |
| 30 Sep 18 | 0 | -30 | 12 | 23 |
| 30 Jun 18 | 0 | -30 | 9 | 24 |
| 31 Mar 18 | 0 | -32 | 8 | 25 |
| 31 Dec 17 | 0 | -31 | 8 | 24 |
| 30 Sep 17 | 0 | -30 | 7 | 23 |
| 30 Jun 17 | 0 | -36 | 9 | 25 |
| 31 Mar 17 | 0 | -31 | 8 | 20 |
| 31 Dec 16 | 0 | -26 | 7 | 16 |
| 30 Sep 16 | 0 | -21 | 5 | 11 |
| 30 Jun 16 | 0 | -8 | 1 | 4 |
| 31 Mar 16 | 0 | -7 | 1 | 3 |
| 31 Dec 15 | 0 | -7 | 1 | 2 |
Quality Earnings: YDO1 is currently unprofitable.
Growing Profit Margin: YDO1 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: YDO1 is unprofitable, and losses have increased over the past 5 years at a rate of 33.3% per year.
Accelerating Growth: Unable to compare YDO1's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: YDO1 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.5%).
Return on Equity
High ROE: YDO1 has a negative Return on Equity (-92.18%), as it is currently unprofitable.